High Dose Vitamin C Formula

Energize | Reduce Fatigue | Support Health

high dose vitamin c intravenous

Adjunctive cancer treatment with high dose vitamin C by intravenous delivery is focused on improving the side effects commonly seen with cancer treatments. Studies that evaluated for the use of high dose vitamin c to patients undergoing concurrent cancer therapies have found that the IV high dose vitamin c reduces nausea and fatigue, and helps to improve energy [1-5]. 


Intravenous Vitamin C is more effective at raising the concentration of the vitamin in the blood than taking an oral supplement. IV Vitamin C can achieve concentrations 50x or more higher when compared to oral supplementation. The high concentration of vitamin c is believed to be beneficial for cancer therapies as it increases the production of hydrogen peroxide in the extracellular compartment, and this can cause cell death in cancer cells, while normal cells seem to show little sensitivity to the hydrogen peroxide. It also has a pro-oxidant effect which creates free radicals (contrary to the usual antioxidant effect of low dose vitamin c) [6-8].


High dose vitamin C may help to slow cancer progression when used adjunctively to conventional cancer treatments. There are observations in studies that the disease process of cancer depletes the body of Vitamin C, and why its administration may be crucial during treatment [9].

High dose vitamin c is never used as a monotherapy (on its own), but only adjunctive to conventional care. To date, there are limited high-quality clinical trials and the utility of high-dose vitamin c remains uncertain. Although, the limited trials done thus far demonstrate benefits and good tolerability [9].


Prior to starting any therapies it is important to discuss with benefits and risks with your oncologist and a naturopathic doctor. 


  1. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy Ann Oncol 2008; 19: , 2008. (2008). Annals of Oncology, 19(12), 2095–2095.

  2. Stephenson, C. M., Levin, R. D., Spector, T., & Lis, C. G. (2013). Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 72(1), 139–146.

  3. Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014). High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy. Science Translational Medicine, 6(222).

  4. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy Ann Oncol 2008; 19: , 2008. (2008). Annals of Oncology, 19(12), 2095–2095.

  5. Yeom, C. H., Jung, G. C., & Song, K. J. (2007). Changes of Terminal Cancer Patients Health-related Quality of Life after High Dose Vitamin C Administration. Journal of Korean Medical Science, 22(1), 7.

  6. Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Levine, M. (2004). Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Annals of Internal Medicine, 140(7), 533.

  7. Chen, Q., Espey, M. G., Sun, A. Y., Lee, J.-H., Krishna, M. C., Shacter, E., Levine, M. (2007). Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proceedings of the National Academy of Sciences, 104(21), 8749–8754.

  8. Chen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Levine, M. (2005). Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proceedings of the National Academy of Sciences, 102(38), 13604–13609.

  9. Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M. (2018). Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. Current Oncology, 25(2), 139.